Eli Lilly and Company
LLY
$989.87
$22.882.37%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 168.07% | 50.52% | 475.34% | 90.78% | 23.01% |
| Total Depreciation and Amortization | 9.94% | 20.71% | 0.69% | 15.47% | 15.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -150.22% | -64.66% | -31.05% | -52.92% | 560.58% |
| Change in Net Operating Assets | 50.54% | -65.21% | 12,428.57% | -61.74% | -92.10% |
| Cash from Operations | 220.11% | 30.34% | 138.04% | 110.54% | 42.88% |
| Capital Expenditure | -54.04% | -70.21% | -54.56% | -38.56% | -53.10% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -37,100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 71.13% | 66.10% | 86.98% | -425.95% | -863.41% |
| Cash from Investing | -16.79% | -45.87% | 25.52% | 16.55% | -184.73% |
| Total Debt Issued | -72.53% | -100.00% | 35.08% | -- | 0.13% |
| Total Debt Repaid | 59.44% | -100.01% | -32.44% | -69.86% | 64.48% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -96.33% | 26.59% | -58.73% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -15.01% | -15.21% | -14.93% | -14.89% | -15.12% |
| Other Financing Activities | 13.85% | 45.32% | 36.15% | -280.00% | -75.99% |
| Cash from Financing | -351.45% | -1,176.63% | 151.30% | -180.03% | 543.30% |
| Foreign Exchange rate Adjustments | -49.24% | 84.35% | -86.03% | 562.25% | 471.83% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,034.86% | -2,388.66% | 4,312.65% | -62.98% | 51.17% |